The global human recombinant insulin market is expected to expand at a CAGR of 7.2% during the forecast period (2018 - 2026), owing to increasing technological advancement in recombinant human insulin
by various key players.
Any insulin formulation, including recombinant human insulin
and analogues, can cause lipoatrophy, and so it seems to be more a problem of structured diabetes education with daily needle change and rotating of in-jection site than a matter of insulin preparation (2), (8).
Growth hormone insensitivity (GHI); Recombinant human insulin
like growth factor- 1 (IGF-1); IGF-1 deficiency.
A unique feature of the LC-MS/MS insulin assay reported here is the consistency and harmonization of the NIBSC insulin standard and the synthesized recombinant human insulin
. Reference to the gold standard WHO reference reagent purchased directly from NIBSC with a designated biological activity of 3 IU per vial should help to avoid the standardization issues that have plagued the currently available antibody-based immunoassays, which each use their own working standards developed by the manufacturers.
The first biosimilar pharmaceutical produced in 1982 for clinical use was recombinant human insulin
(Humulin; Eli Lilly).
"The diabetes idea for us is a much wider one than just promotion and sale of recombinant human insulin
or insulin analogues," he explains.
Biocon and Pfizer have entered into a strategic agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: recombinant human insulin
, Glargine, Aspart and Lispro.
The first biotechnology product, Recombinant Human Insulin
(Insuget), was developed in 2007-2008 and was launched in the first quarter of 2009.
Khalid said the company's total investment in Pakistan was Rs 4 billion in the last three years, including investment in manufacturing technology of the first locally manufactured recombinant human insulin
. It plans to invest an equal amount in the coming two years in new technologies that would result in local manufacturing of drugs that are currently being imported at high costs.
9 June 2010 - Danish biotech company Zealand Pharma A/S has agreed with its French partner Sanofi-Aventis (EPA: SAN) on the development and commercialisation of Zealand's product Lixisenatide for the treatment of type-2 diabetes in combination with Sanofi-Aventis's Lantus, a recombinant human insulin
Insulin glargine (Lantus, Sanofi-Aventis) is a long-acting recombinant human insulin
that is frequently used to treat diabetic cats.
US-China Drug Safety Memorandum: Designated Drugs SFDA-Designated Drugs Recombinant Human Insulin
Lysine Fat and Lysine Salt Cefoperazone and its salts Paclitaxel injection Penicillin and its finished dosage form Diagnostic kit for blood screening, specifically, for HIV/AIDS and Hepatitis B & C HHS/FDA-Designated Drugs: Gentamicin sulfate Atorvastatin Sildenafil Dietary supplements intended for erectile dysfunction or sexual enhancement Human Growth Hormone Oseltamivir Cephalosporins manufactured in facilities that also manufacture non-cephalosporin drugs Glycerin